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In this issue of Blood, Kärkkäinen and colleagues demonstrate, using a VEGF-D transgenic mouse model, that overexpression of human VEGF-D induces a proangiogenic phenotype, increases regeneration after ischemic injury, and also induces the formation of tumors. V ascular endothelial cell growth factor D (VEGF-D) was identified in the mid -1990s as a c-fos-induced growth factor sharing structural and functional characteristics with VEGF-C and displaying lymphangiogenic properties through activation of the lymph vasculature receptor VEGFR-3. 1, 2 In humans, VEGF-D binds to VEGFR-3 as well as to VEGFR-2, of which the latter is the receptor for VEGF-transducing signals leading to formation of blood vessels. The study by Kärkkäinen et al, which reports the generation of human VEGF-D transgenic mice using a method based on perivitelline oocyte injection of a lentiviral vector expressing the growth factor, provides new insight into the biology of VEGF-D. 3 The transgenic mice, constitutively expressing VEGF-D in many organs, clearly demonstrate a proangiogenic phenotype with enhanced blood vessel capillary density in muscle tissue while a lack of increased numbers of lymphatic capillaries suggest no effect on lymphangiogenesis. The enhanced healing capacity of transgenic mice after ischemic injury was also suggested to be mainly due to VEGFR-2 signaling and enhanced blood vessel formation. These results are consistent with earlier studies where knockout approaches were used, demonstrating that VEGF-D does not have a major lymphangiogenesis function. 4 This study by Kärkkäinen et al, as well as studies by others, may suggest the potential for growth factor therapy of ischemic diseases. In addition, discussions on the use of therapeutic lymphangiogenesis for diseases with associated lymphedema after surgery or radiotherapy are ongoing. Although this is an attractive approach, (lymph-)angiogenic growth factors can enhance vascular permeability, which may pose an additional problem.
In the present study, it was observed that mice with human VEGF-D incorporated in their genome developed spontaneous tumors in epithelia with a preference for induction of mammary gland adenocarcinomas. This interesting and unexpected finding may limit the therapeutic use of VEGF-D. Therapeutic intervention by neutralization of VEGF-D for diseases characterized by excessive angiogenesis, such as cancer, may therefore be a more promising approach. Indeed, inhibition of metastatic spread, microhemorrhage, and collapse of tumor vessels has been described in mice injected with blocking monoclonal antibodies 5 or soluble VEGFR-3. 6 Although it was reported before that VEGF-D can facilitate tumor growth and support metastasis formation, probably due to enhanced vessel/tumor cell interaction surface, it is very interesting to question how VEGF-D can give rise to spontaneous tumors. It suggests that either the growth factor itself can transform normal epithelial cells into tumor cells -a hypothesis that is currently considered unlikely -or that normal epithelial cells are continuously challenged by genetic or epigenetic alterations, having more chance to result in tumor cells (normally a very rare event) when a more angiogenic environment is available. In the latter situation, tumor growth may be supported by better supply of oxygen and nutrients, by enhanced vascular permeability, a beneficial cytokine/chemokine milieu, or by a changed adhesion molecule profile. Another possibility is the VEGF-Dmediated generation of an immune-privileged situation. Indeed, VEGF-D has been reported to contribute, in a concerted action with other angiogenic growth factors, to endothelial cell anergy and subsequent escape from immune surveillance. 7 All these conditions are supportive for an anti-VEGF-D strategy to intervene with tumor growth. Such an approach would potentially have the same problems as current anti-VEGF strategies in the clinic, 8 
